Report
Description
Report Description
Systemic Lupus Erythematous (SLE) is a chronic autoimmune disease which causes the immune
system to mistakenly attack health body tissue. In SLE, body immune system can affect any part
of the body, such as joints, organs, eyes, skin, etc. Often SLE can result in symptoms such as
malar rash, discoid lesions, sub-acute cutaneous lesions, photosensitivity, oral ulcers, arthritis,
serositis, nephropathy, neurologic involvement, thrombocytopenia, haemolytic anemia, fever,
Raynaud’s phenomenon, livedo reticularis, thrombosis, and myositis. It is also known as a
disease of flare-ups and remissions and can range from mild to life threatening severity. It is also
called as drug-induced lupus erythematosus due to common observation against drugs such as
isoniazid, hydralazine and procainamide. Currently, there is no complete treatment for SLE.
While only two biologic agents have been approved by FDA to treat SLE, synthetic drugs are still
the mainstay of therapy in SLE. Based on available evidence, azathioprine and mycophenolate
mofetil are the drugs of first choice. Hydroxychloroquine should be considered an anchor drug
in SLE because of the multiple beneficial effects of this agent.
Systemic Lupus Erythematous (SLE) Drugs Market: Drivers & Restraints
Global Systemic Lupus Erythematous (SLE) Drugs market is projected to grow due to high
prevalence of autoimmune diseases particularly systemic lupus erythematous (SLE). Major
drivers for global systemic erythematous drugs market are development of novel SLE therapies,
increasing availability of bio similar drugs and increasing support for emerging research areas for
new drug molecules. At the same time, increasing awareness of disease diagnosis and treatment
as well as consistent research and development processes for novel drug molecules are
important drivers for global lupus erythematous market.